颅骨牵引术最初的报告

原著标题:Skeletal traction for dislocation of the cervicalspine.Report of a case.刊载杂志:South.Surg,1933,2:156-159.原著作者:Crutchfield William Gayle(1900-?)美国弗吉尼亚州里士满医科大学神经外科本文报告1例经颅骨的颈椎牵引治疗方法,患者,女,22岁,因交通事故致第2颈椎骨折脱位,因同时合     

师生互评对促进临床带教质量提高的探索

我院是一所二级甲等综合性医院（目前正在申报三乙医院），它也是我省首批列入高校临床教学基地的教学医院。为了能培养一批对社会有用的优秀护理人才，医院护理部非常重视临床教学带教工作，护理部在2000年开始采用师生定期相互评价方法，来促进临床教学带教工作。下面将我院这一做法与体会予以简述：     

康复新液联合裸花紫珠胶囊治疗口腔种植体周围软组织炎临床研究

目的:探讨康复新液联合裸花紫珠胶囊治疗口腔种植体周围软组织炎临床疗效。方法:选取80例口腔种植体周围软组织炎患者作为研究对象,采用随机数字表法分为对照组(n=40)和研究组(n=40)。对照组给予康复新液治疗,在此基础上研究组加用裸花紫珠胶囊。对比两组临床疗效,治疗前后中医证候积分、牙龈出血指数(SBI)、探诊深度(PD)、菌斑指数(PLI)及龈沟液中白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)水平。结果:研究组总有效率95.00%高于对照组80.00%,差异具有统计学意义(P<0.05)。治疗后研究组中医证候积分低于对照组,差异具有统计学意义(P<0.05)。研究组SBI、PLI及PD均低于对照组,研究组龈沟液中IL-1β和IL-6水平均低于对照组,差异有统计学意义(均P<0.05)。结论:康复新液联合裸花紫珠胶囊治疗种植体周围炎效果较好,可降低出血指数,去除菌斑,减轻种植体周围炎症。     

成人安氏Ⅱ1类与Ⅱ2类错(牙合)软组织侧貌对比研究

目的:对比成人安氏Ⅱ1类错(牙合)与安氏Ⅱ2类错(牙合)颌面部形态特点,通过对比研究二者颌面部形态差异为临床诊断和治疗工作提供参考依据.方法:选择安氏Ⅱ1类与安氏Ⅱ2类错(牙合)患者共60例,性别比1∶1,年龄＞18岁.应用X线头影测量技术对选取的22项软组织指标进行测量.结果:鼻唇角、上唇倾角、上唇突角、下唇突角、上唇厚、下唇突点-E线距的差异有统计学意义(P＜0.05),其中下唇倾角(P＜0.01).结论:成人安氏Ⅱ1类比Ⅱ2类的上下唇均前突,且其上唇厚度小于安氏Ⅱ2类错(牙合).     

帕拉米韦治疗流行性感冒的疗效及安全性分析

目的:帕拉米韦是新型的抗病毒药物,本研究拟评价帕拉米韦治疗流行性感冒的临床安全性。方法:以北京大学第三医院感染疾病科发热门诊就诊的流行性感冒患者89例为研究对象,所有患者均给予帕拉米韦氯化钠注射液3 mg·mL~(-1)治疗,单次静脉滴注,评价其发热、呼吸道和全身症状的缓解情况和药物的安全性。结果:患者平均年龄(28.31±8.30)岁。诊断为甲型流感84例,乙型流感5例。治疗后7 d随访,发热均缓解,缓解时间(24.92±14.44) h。主要不良事件包括消化道症状5例(5.62%),神经系统症状3例(3.37%)。心电图由治疗前的窦性心律变为治疗后的窦性心动过缓9例(10.11%),窦性心律不齐6例(6.74%),2例治疗后QTc间期延长。治疗前正常,治疗后2例丙氨酸氨基转移酶异常,15例(16.85%)甘油三酯升高,6例(6.74%)网织红细胞异常。无严重不良事件。结论:帕拉米韦治疗流行性感冒的安全性相对较高。     

咳嗽变异性哮喘吸入糖皮质激素的临床疗效观察

目的:研究咳嗽变异性哮喘患者吸入糖皮质激素后治疗的临床疗效。方法:治疗组96例,给予丙酸氟替卡松吸入气雾剂;对照组72例,不进行治疗。观察3个月后两组患者的情况。结果:试验组和对照组的疗效差异有统计学意义(χ2=4.33;P<0.05)。表明:试验组和对照组之间,对照组的临床疗效优于试验组,差异有统计学意义(P<0.05)。结论:咳嗽变异性哮喘吸入糖皮质激素治疗有效。     

Efficacy of preoperative intracavitary brachytherapy and surgery in patients with stage ⅠB2 and ⅡA bulky cervical cancer

Objective To analyze the outcomes of preoperative intracavitary brachytherapy plus sur-gery in patients with stage ⅠB2 and ⅡA bulky cervical cancer. Methods From January 2001 to January 2007, 77 patients with stage ⅠB2 and ⅡA bulky cervical cancer were included. The diameter of primary tumor was greater than 4 cm. Preoperative intracavitary brachytherapy with the total dose of 20-30 Gy (0.5 cm below the vaginal mucosa) was delivered by 2-3 fractions, one fraction per week. After an interval of 10-14 days, the efficacies of radiotherapy were evaluated and radical hysterectomy with pelvic lymphade-nectomy was performed. Then the treatment complications, clinicopathological characteristics, survival and recurrence were analyzed. Results The tumor shrinkage was observed in all the patients after intracavitary brachytherapy. The CR, PR and SD were 5% (4/77), 36% (28/77) and 58% (45/77), respectively. Radical hysterectomy was successfully performed in all patients. The complications of the combined therapy were mild and only 5 patients had grade Ⅱ or less hematological or gastrointestinal toxicities. The 5-year o-verall survival rate and pelvic recurrence rate were 83% and 12%, respectively. Conclusions Preoperative intracavitary brachytherapy of 20-30 Gy plus surgery is effective in the treatment of stage ⅠB2 and ⅡA bulky cervical cancer without increasing the treatment complications.